UNITY Biotechnology IncNASDAQ:UBX
- LAST PRICE1.4700
- TODAY'S CHANGE (%)-0.0200 (-1.3423%)
- Bid / Lots1.4700/ 6
- Ask / Lots1.4800/ 1
- Open / Previous Close1.5000 / 1.4900
- Day Range
- 52 Week Range
- Volume81,742
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | UBX |
|---|---|---|
| 09:32 ET | 16711 | 1.51 |
| 09:34 ET | 100 | 1.49 |
| 09:50 ET | 500 | 1.475 |
| 10:06 ET | 100 | 1.47 |
| 10:37 ET | 600 | 1.48 |
| 10:39 ET | 300 | 1.48 |
| 10:42 ET | 4000 | 1.475 |
| 10:44 ET | 200 | 1.4829 |
| 10:50 ET | 257 | 1.48 |
| 10:51 ET | 100 | 1.49 |
| 11:13 ET | 100 | 1.49 |
| 11:20 ET | 469 | 1.475 |
| 11:22 ET | 563 | 1.475 |
| 11:24 ET | 102 | 1.4799 |
| 11:26 ET | 136 | 1.4712 |
| 11:31 ET | 1000 | 1.4804 |
| 11:33 ET | 100 | 1.48 |
| 11:40 ET | 576 | 1.48 |
| 11:42 ET | 127 | 1.4701 |
| 11:45 ET | 600 | 1.48 |
| 11:49 ET | 300 | 1.475 |
| 11:51 ET | 29502 | 1.47 |
| 11:58 ET | 100 | 1.46 |
| 12:07 ET | 100 | 1.465 |
| 12:20 ET | 671 | 1.46 |
| 12:32 ET | 100 | 1.465 |
| 12:43 ET | 342 | 1.465 |
| 12:56 ET | 455 | 1.4689 |
| 01:01 ET | 998 | 1.4661 |
| 01:21 ET | 100 | 1.465 |
| 01:26 ET | 100 | 1.4696 |
| 01:28 ET | 200 | 1.46 |
| 01:33 ET | 200 | 1.47 |
| 01:37 ET | 2000 | 1.46 |
| 01:39 ET | 201 | 1.4695 |
| 02:08 ET | 543 | 1.47 |
| 02:09 ET | 915 | 1.4699 |
| 02:11 ET | 450 | 1.4699 |
| 02:13 ET | 100 | 1.47 |
| 02:15 ET | 100 | 1.47 |
| 02:18 ET | 138 | 1.465 |
| 02:31 ET | 200 | 1.4699 |
| 02:36 ET | 175 | 1.47 |
| 02:42 ET | 1000 | 1.465 |
| 02:44 ET | 359 | 1.47 |
| 02:47 ET | 1441 | 1.47 |
| 03:02 ET | 100 | 1.48 |
| 03:03 ET | 460 | 1.4799 |
| 03:05 ET | 100 | 1.4799 |
| 03:09 ET | 4100 | 1.4701 |
| 03:12 ET | 102 | 1.4795 |
| 03:21 ET | 100 | 1.48 |
| 03:25 ET | 1448 | 1.4787 |
| 03:41 ET | 200 | 1.48 |
| 03:43 ET | 100 | 1.47 |
| 03:56 ET | 200 | 1.47 |
| 03:59 ET | 425 | 1.47 |
Yesterday
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME, from 8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 16, 2024
DJ Unity Biotechnology Is Maintained at Buy by HC Wainwright & Co., from 7:15AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:15AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 15, 2024
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates, from 7:00AM ET on Monday Apr 15, 2024 by Dow Jones
7:00AM ET on Monday Apr 15, 2024 by Dow Jones*DJ Unity Biotechnology 4Q Loss/Shr 28c >UBX, from 7:00AM ET on Monday Apr 15, 2024 by Dow Jones
7:00AM ET on Monday Apr 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
UNITY Biotechnology Inc | 25.0M | -0.5x | --- |
Sensei Biotherapeutics Inc | 25.0M | -0.8x | --- |
Vaxxinity Inc | 25.3M | -0.3x | --- |
Enlivex Therapeutics Ltd | 24.6M | -1.0x | --- |
Bioxytran Inc | 25.5M | -4.4x | --- |
Serina Therapeutics Inc | 25.0M | -0.7x | --- |
Company Information
Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.
Contact Information
- Headquarters
- 285 EAST GRAND AVENUESOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-416-1192
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Keith Leonard
- Chief Executive Officer, Director
- Anirvan Ghosh
- Chief Financial Officer, Head of Corporate Development
- Lynne Sullivan
- General Counsel and Corporate Secretary
- Alexander Nguyen
- Lead Independent Director
- Paul Berns
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $25.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.87 |
EPS | $-2.75 |
Book Value | $1.69 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
